EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte Studie

Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects

You-Xuan Wu, Xue-Feng Zhong, Xiao-Min Li, Wan-Li Liu, Yan-Xin Zhang, Qiu-Ying Shen, Su-Mei Xu, Ping-Sheng Xu

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1269 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, 2023. Written by You-Xuan Wu and 7 co-authors. Institution: Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, PR China. Major MEDLINE topics: Nifedipine. Cited 2 times so far (Crossref); 14 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We compared newly developed delayed‐release oral tablets (test) of 30‐mg nifedipine (NFP) with its marketed counterpart (30 mg; reference) in healthy adult Chinese volunteers to assess the former's bioequivalence. This was a randomized, open‐label, four‐period, crossover trial study including fasting and fed trials. The participants were randomly administered test or reference formulations (1:1 ratio) throughout each period, with a 7‐day washout period. In the next session, they were administered the alternate products. Liquid chromatography–tandem mass spectrometry and WinNonlin software were used to evaluate the bioequivalence of the maximum plasma concentration (C max ) of NFP and the area under the concentration–time curve (AUC). In total, 46 and 48 people participated in the fasting and postprandial trials. In both groups, the 90% confidence intervals of geometric mean ratios of C max , AUC from time zero to time t, and AUC from time zero to infinity were in the equivalence range (80%–125%). When NFP was administered concomitantly with a high‐fat meal, time to maximum concentration was approximately twofold earlier, absorption was approximately 4.8% less, and C max exhibited a slight change relative to those under fasting conditions. Moreover, no serious adverse events were recorded in the participants. The present findings confirm the bioequivalence of test and reference formulations of NFP tablets under fasting and postprandial conditions.

Subjects

MeSH terms (MEDLINE)

NifedipineAdultHumansTherapeutic EquivalencyHealthy VolunteersDelayed-Action PreparationsArea Under CurveHalf-LifeTabletsAdministration, Oral

Author keywords

bioequivalence evaluationfood effectsnifedipinepharmacokinetics

Substances

NifedipineDelayed-Action PreparationsTablets

Authors and institutions

  • Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, PR China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, PR China.

Cite

APA

Wu, Y. X., Zhong, X. F., Li, X. M., Liu, W. L., Zhang, Y. X., Shen, Q. Y., Xu, S. M., & Xu, P. S. (2023). Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1269

Vancouver

Wu YX, Zhong XF, Li XM, Liu WL, Zhang YX, Shen QY, et al. Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1269

BibTeX
@article{Wu2023,
  author = {Wu, You-Xuan and Zhong, Xue-Feng and Li, Xiao-Min and Liu, Wan-Li and Zhang, Yan-Xin and Shen, Qiu-Ying and Xu, Su-Mei and Xu, Ping-Sheng},
  title = {Pharmacokinetics of Nifedipine‐Sustained Release Tablets in Healthy Subjects After a Single Oral Administration: Bioequivalence Analysis and Food Effects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1269}
}
Start for free →